The Translation of Next Generation Therapeutics

Tony Hitchcock

When we look at the current trends with what we can refer to as “next generation therapeutics”, whether it be ADCs or cell and gene therapy products, one trend is very clear, products are becoming increasingly complex in their nature. Certainly, the complexity of the manufacturing processes used to produce them clearly reflects this; hand in hand with ever increasing product development costs and timelines. Many of these products are being developed by small start-up companies frequently funded...
To continue reading this story get free access